Effects of therapy with urokinase (UK) and with recombinant tissue plasminogen activator (rtPA) were compared in patients with acute myocardial infarction (AMI). To achieve homogenous therapeutic conditions the comparison was restricted to patients having their first AMI and to cases of clinically successful thrombolytic therapy (defined by non-invasive criteria, such as a 50% decrease in elevated ST-segment in the worst lead of a 12 lead ECG within 300 min after onset of thrombolytic therapy, complete pain resolution during thrombolytic therapy, and later confirmed by angiography 10 days after AMI). Effects of UK and rtPA on continuous multilead ST-segment analysis and cardiac proteins (creatine kinase and its isoenzyme CK-MB, aspartate transaminase and hydroxybutyrate dehydrogenase) were analyzed during 24 hours following onset of therapy.
a new angina event after onset of thrombolytic therapy. None of the patients developed ventricular fibrillation or cardiac arrest during the first 24h after onset of thrombolytic therapy and no patient succumbed to fatal arrhythmias. Thrombolytic therapy: All patients were treated with heparin (1000 IU/60 kg/h i.v.), aspirin (500mg i.v.) and nitroglycerine (2mg/h, adapted to blood pressure, i.v.). Analgesics (morphine, FentanylR or FortralR) were given in the prehospital phase and, if necessary, on admission. Only those patients with definite pain resolution during and after thrombolytic therapy entered the study. For thrombolytic therapy either urokinase (UkidanR, Serono, Germany) or recombinant tissue plasminogen activatort (ActilyseR, Thomae, Germany) were randomly administered according to the study protocol. UK was given as an i.v. bolus of 1.5 million IU followed by a continuous 1 hour infusion of another 1.5 million IU; rtPA was infused at a front-loaded, weight-adjusted dose (total dose per 80kg body weight: 100mg adminstered over 90min; 15mg as a bolus over 2min, then 50mg over 30min and finally 35mg over 60min),3,7) with both dosages recommended by the American Heart Association. The therapies were randomly distributed in a blinded, prospective setting. The patients gave their informed consent to thrombolytic therapy. They were not aware of which of the two treatments was administered. Study design and continuous ST-segment analysis: Immediately after admission to the intensive care unit a 12 lead ECG was taken, then the patients were hooked up to a continuous multi-lead ECG monitoring system with Holter ECG electrode positioning. EGG, ST-segment vectors from 3 leads (I, II, III, V, or CM5, according to the infarction), heart rate, and blood pressure were continuously recorded by the Data Management System HP78365A (Hewlett Packard, Germany). The ECG lead with the maximal ST deviation was used for evaluation of the ST vector, lead III for inferior infarctions, and CM5
(precordial) for anterior AMI. Only cases with prominent initial ST-segment elevation in recordings from these leads (more than a third of the amplitude of the QRS vector; no pacemaker) were included in the study. For ST-segment analysis the following algorithm was applied: the isoelectric point was set to the level present 80msec before the R peak; the ST-segmentpoint was allocated 120msec after the R peak. These values were individually controlled prior to analysis and, if necessary, manually adapted. The difference between isoelectric point and ST-segment-point, representing the ST-segment vector, was measured on line and documented by a printout. ST-segment vectors were assessed before initiation of thrombolytic therapy. For further evaluation ST-segment values were normalized with the maximal ST elevation point prior to thrombolytic therapy set to 100%. The QRS duration was controlled from the 12 lead ECG on admission and 24 hours after thrombolysis. The individual courses of ST-segments thereafter were still more variable in patients treated with UK than with rtPA ( Figure 1 ). Cardiac proteins and hemoglobin: Measures of cardiac proteins indicated a stronger increase in the CK plasma levels after rtPA than after UK treatment.
There was no significant difference in the increase in CK-MB and GOT between the two groups (Figure 2) , although mean values after rtPA exceeded those after UK. HBDH plasma levels 8 and 24 hours after rtPA exceeded those after UK; actually their maxima were not reached within 24 hours. Hemoglobin values did not differ between the groups.
DISCUSSION
In patients after a first AMI and with clinical criteria for successful reperfusion, continuous multilead ECG monitoring showed a significantly faster ST-segment recovery following treatment with rtPA than UK. The time to 80% ST recovery after rtPA treatment averaged 150 minutes. In contrast, following UK treatment the average ST-segment reduction did not exceed 80% until 12 hours after onset of treatment. So far, continuous ST-segment analysis has been described only during thrombolytic therapy with rtPA.4) Myocardial salvage after successful reperfusion has been examined after treatment with rtPA, but not after UK treatment.5) The strict criteria of selecting only patients without previous myocardial infarction and with successful reperfusion in this study set the stage for a more sensitive comparison of the in vivo effects of the two pharmacodynamically different thrombolytics.
Fast resolution of the ST-segment elevation after reperfusion is known to preceed changes associated with the development of myocardial tissue damage.1) Thus, the prolonged time to ST-segment recovery after UK therapy compared to rtPA in this study might reveal a disadvantage of UK therapy with a reduced myocardial salvage compared to rtPA treatment.
In this study the earlier ST-segment recovery after rtPA treatment was accompanied by a shorter time until accelerated idioventricular rhythms occurred. Accelerated idioventricular rhythms may indicate that reperfusion occurred.9) In fact, here they accompanied the acceleration of ST-segment reduction, indexing reperfusion, after rtPA therapy.
Angiography performed 10 days after AMI confirmed reperfusion, except for a prominent stenotic lesion in one patient after rtPA treatment, and another significant stenosis indicated by a TIMI flow grade 1 in one patient treated with UK. Considering that angiography took place quite a long time after AMI , it is likely that in both cases silent restenotic processes developed after thrombolytic therapy.
Plasma concentrations of myoglobin (on admission), CK-MB and GOT (prior to, 8 hours and 24 hours after treatment) did not differ significantly between the groups, indicating that the area at risk was comparable in both groups. As expected after successful reperfusion, plasma levels of CK and CK-MB reached a maximum within 8 hours after thrombolytic therapy.11) However, the levels of CK and also of HBDH after rtPA treatment exceeded those after UK treatment (8 and 24 hours after onset of therapy). An increase in plasma CK and HBDH concentrations may be an indicator for hemolytic processes and blood cell apoptosis, but there were no signs of bleeding complications (such as hematuria or manifest bleeding) or differences in hemoglobin levels in the 19 patients. Thus, hemolysis cannot account for the finding of increased plasma concentrations of CK and HBDH after rtPA treatment.
However, though myoglobin and CK-MB did not reveal differences in the infarcted area between the two treatment groups, the wash-out of CK and HBDH was increased after rtPA. Whether this increase originated from more extended infarctional damage in the rtPA group, or was related to a local, enhanced action of rtPA on the myocardium at risk, is presently unclear. Assuming a greater infarcted area in the rtPA treated group than in the UK group, the accelerated reduction of the ST-segment elevation following rtPA treatment would be indicative of an even greater advantage of rtPA over UK in in vivo thrombolysis.
In conclusion, thrombolysis with rtPA was superior to thrombolysis with UK in accelerating ST-segment reduction in patients with successful thrombolytic therapy of a first myocardial infarction. Accelerated ST-segment regression correlates with improved myocardial salvage. Hence, beneficial effects of rtPA on myocardial salvage may be deduced from the present results.
